Recruiting NA INTERVENTIONAL 2-arm NCT04498767

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (OligoRARE)

Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial

Sponsor: Anticancer Fund, Belgium

Conditions Bladder Cancer Colon Cancer Esophageal Cancer Gastric Cancer Gynecologic Cancer Head and Neck Cancer Hepatobiliary Cancer Melanoma Oligometastasis Pancreatic Cancer Renal Cancer Sarcoma Skin Cancer Small Bowel Cancer Upper Urinary Tract Carcinoma

Interventions Palliative RT Stereotactic body radiotherapy

Updated 14 times since 2020 Last updated: Aug 23, 2024 Started: Jun 10, 2021 Primary completion: Aug 1, 2028 Completion: Feb 1, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Bladder Cancer and Colon Cancer and is currently actively recruiting participants. Anticancer Fund, Belgium leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Recruiting NA
Sep 2024 — Sep 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jun 2024 — Jul 2024 [monthly]

Recruiting NA
Mar 2024 — Jun 2024 [monthly]

Recruiting NA

▶ Show 9 earlier versions

Dec 2023 — Mar 2024 [monthly]

Recruiting NA
May 2023 — Dec 2023 [monthly]

Recruiting NA
Mar 2023 — May 2023 [monthly]

Recruiting NA
Jun 2022 — Mar 2023 [monthly]

Recruiting NA
Apr 2022 — Jun 2022 [monthly]

Recruiting NA
Mar 2022 — Apr 2022 [monthly]

Recruiting NA
Sep 2021 — Mar 2022 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting · Phase: PHASE3 → NA
Jan 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE3
Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anticancer Fund, Belgium
European Organisation for Research and Treatment of Cancer - EORTC
Rising Tide Foundation

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderlecht, Belgium , Bern, Switzerland , Birmingham, United Kingdom , Gdansk, Poland , Ghent, Belgium , Hamburg, Germany , Lille, France , London, United Kingdom , Milan, Italy , Villejuif, France and 3 more locations